TBCRC026

Please Note: This trial is no longer enrolling new participants

A Phase 2 Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) with Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients with Primary Operable HER2-Positive Breast Cancer

TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer
Connolly RM;Leal JP;Solnes L;Huang CY;Carpenter A;Gaffney K;Abramson V;Carey LA;Liu MC;Rimawi M;Specht J;Storniolo AM;Valero V;Vaklavas C;Krop IE;Winer EP;Camp M;Miller RS;Wolff AC;Cimino-Mathews A;Park BH;Wahl RL;Stearns V;
Multiplex Spatial Proteomic Analysis of HER2-Positive Breast Tumors Reveals Unique Molecular and Immunologic Features Associated With Treatment Response
Hennessy MA;Cimino-Mathews A;Carter JM;Kachergus JM;Ma Y;Leal JP;Solnes LB;Denbow R;Abramson VG;Carey LA;Rimawi M;Specht J;Storniolo AM;Valero V;Vaklavas C;Winer EP;Krop IE;Wolff AC;Wahl RL;Perez EA;Huang CY;Stearns V;Thompson EA;Connolly RM;